Immunovant and Roivant Sciences said Wednesday their rare disease drug succeeded in a final-phase study, but the duo won't seek approval.

The companies reported Wednesday that batoclimab showed improvements in myasthenia gravis patients in a Phase 3 trial.

In a report released today, Yaron Werber from TD Cowen maintained a Buy rating on Roivant Sciences (ROIV – Research Report). The company’s ...

Cargo was founded by two highly acclaimed cell-therapy researchers. The company raised over $500 million to develop ...

Roivant Sciences operates as a biopharmaceutical company, developing novel therapies for diseases with significant unmet needs. The company's distinct business model involves creating "Vants," or ...

Increased operational expenses and reduced cash reserves were cited. Roivant Sciences follows a unique approach to drug development, focusing on creating independent subsidiaries known as "Vants ...

Roivant Sciences Ltd. (NASDAQ:ROIV), a pharmaceutical company with a market capitalization of $7.8 billion and a "GOOD" financial health rating according to InvestingPro, disclosed on Thursday ...

Pivotal study in MG met primary endpoint of change from baseline in MG-ADL in AChR+ population at 12 weeks, with a 5.6 point improvement in the ...

Bank of New York Mellon Corp raised its stake in Roivant Sciences Ltd. (NASDAQ:ROIV – Free Report) by 17.4% during the fourth quarter, according to the company in its most recent 13F filing with the ...

Roivant Sciences Ltd. engages in the biopharmaceutical business, which engages in the development of transformative medicine. Its product portfolio includes Vtama, Batoclimab, Brepocitinib ...

Roivant Sciences Ltd. has a 52-week low of $9.80 and a 52-week high of $13.06. Roivant Sciences ( NASDAQ:ROIV – Get Free Report ) last posted its quarterly earnings results on Monday, February 10th.